{"id":"https://openalex.org/W7224457214","doi":"https://doi.org/10.3389/fonc.2026.1933091","title":"Sequential colorectal cancer\u2013based therapy including anti-angiogenics and 3rd-line trifluridine/tipiracil-bevacizumab for metastatic urachal adenocarcinoma: a case report","display_name":"Sequential colorectal cancer\u2013based therapy including anti-angiogenics and 3rd-line trifluridine/tipiracil-bevacizumab for metastatic urachal adenocarcinoma: a case report","publication_year":2026,"publication_date":"2026-10-29","ids":{"openalex":"https://openalex.org/W7224457214","doi":"https://doi.org/10.3389/fonc.2026.1933091"},"language":"en","primary_location":{"id":"doi:10.3389/fonc.2026.1933091","doi":"https://doi.org/10.3389/fonc.2026.1933091","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fonc.2026.1933091","pdf_url":"https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1933091/pdf","source":{"id":"https://openalex.org/S2596394214","display_name":"Frontiers in Oncology","issn_l":"2234-943X","issn":["2234-943X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Oncology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1933091/pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5136824750","display_name":"Shahla Abu Naib","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Shahla Abu Naib","raw_affiliation_strings":["Leaders in Oncology Care, HCA Healthcare UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Leaders in Oncology Care, HCA Healthcare UK","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5101707847","display_name":"Marco Gerlinger","orcid":"https://orcid.org/0000-0003-2719-299X","observed_orcids":["https://orcid.org/0000-0003-2719-299X"]},"institutions":[{"id":"https://openalex.org/I166337079","display_name":"Queen Mary University of London","ror":"https://ror.org/026zzn846","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I166337079"]},{"id":"https://openalex.org/I4405264518","display_name":"Barts Cancer Institute","ror":"https://ror.org/0266wrt04","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I166337079","https://openalex.org/I4405264518"]}],"countries":["GB"],"is_corresponding":true,"raw_author_name":"Marco Gerlinger","raw_affiliation_strings":["Barts Cancer Institute, Queen Mary University of London","Leaders in Oncology Care, HCA Healthcare UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Barts Cancer Institute, Queen Mary University of London","institution_ids":["https://openalex.org/I166337079","https://openalex.org/I4405264518"]},{"raw_affiliation_string":"Leaders in Oncology Care, HCA Healthcare UK","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5101707847"],"corresponding_institution_ids":["https://openalex.org/I166337079","https://openalex.org/I4405264518"],"apc_list":{"value":3150,"currency":"CHF","value_usd":3801},"apc_paid":{"value":3150,"currency":"CHF","value_usd":3801},"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.81882681,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"16","issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.5570999979972839,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.5570999979972839,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12695","display_name":"Urinary and Genital Oncology Studies","score":0.3732999861240387,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T13110","display_name":"Colorectal and Anal Carcinomas","score":0.01600000075995922,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/urachal-adenocarcinoma","display_name":"urachal adenocarcinoma","score":0.9919999837875366},{"id":"https://openalex.org/keywords/trifluridine-tipiracil","display_name":"trifluridine/tipiracil","score":0.9070000052452087},{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":0.9990000128746033},{"id":"https://openalex.org/keywords/anti-angiogenic-therapy","display_name":"anti-angiogenic therapy","score":0.9290000200271606},{"id":"https://openalex.org/keywords/anti-vegf-therapy","display_name":"anti-VEGF therapy","score":0.8220000267028809},{"id":"https://openalex.org/keywords/regorafenib","display_name":"regorafenib","score":0.7749999761581421},{"id":"https://openalex.org/keywords/fruquintinib","display_name":"fruquintinib","score":0.996999979019165},{"id":"https://openalex.org/keywords/sequential-therapy","display_name":"sequential therapy","score":0.5260000228881836},{"id":"https://openalex.org/keywords/third-line-therapy","display_name":"third-line therapy","score":0.7400000095367432},{"id":"https://openalex.org/keywords/folfiri","display_name":"FOLFIRI","score":0.7480000257492065},{"id":"https://openalex.org/keywords/xelox","display_name":"XELOX","score":0.9010000228881836},{"id":"https://openalex.org/keywords/oxaliplatin","display_name":"oxaliplatin","score":0.8349999785423279},{"id":"https://openalex.org/keywords/retinopathy","display_name":"retinopathy","score":0.6790000200271606},{"id":"https://openalex.org/keywords/rare-malignancy","display_name":"rare malignancy","score":0.3440000116825104}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9487000107765198},{"id":"https://openalex.org/C2776248978","wikidata":"https://www.wikidata.org/wiki/Q3891664","display_name":"Regorafenib","level":4,"score":0.7358999848365784},{"id":"https://openalex.org/C2780962732","wikidata":"https://www.wikidata.org/wiki/Q422327","display_name":"Oxaliplatin","level":4,"score":0.7164000272750854},{"id":"https://openalex.org/C2776705615","wikidata":"https://www.wikidata.org/wiki/Q1389369","display_name":"FOLFIRI","level":5,"score":0.6890000104904175},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.6554999947547913},{"id":"https://openalex.org/C2779399171","wikidata":"https://www.wikidata.org/wiki/Q1483951","display_name":"Malignancy","level":2,"score":0.5934000015258789},{"id":"https://openalex.org/C2781182431","wikidata":"https://www.wikidata.org/wiki/Q356033","display_name":"Adenocarcinoma","level":3,"score":0.5482000112533569},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5170000195503235},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.46470001339912415},{"id":"https://openalex.org/C2910665457","wikidata":"https://www.wikidata.org/wiki/Q356033","display_name":"Metastatic adenocarcinoma","level":4,"score":0.4235000014305115},{"id":"https://openalex.org/C2777909004","wikidata":"https://www.wikidata.org/wiki/Q420207","display_name":"Capecitabine","level":4,"score":0.3919999897480011},{"id":"https://openalex.org/C2778260052","wikidata":"https://www.wikidata.org/wiki/Q117636","display_name":"FOLFOX","level":5,"score":0.3912000060081482},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.3910999894142151},{"id":"https://openalex.org/C2779013556","wikidata":"https://www.wikidata.org/wiki/Q181876","display_name":"Metastasis","level":3,"score":0.3709999918937683},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.37049999833106995},{"id":"https://openalex.org/C2909234372","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal adenocarcinoma","level":4,"score":0.36399999260902405},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.35199999809265137},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.32120001316070557},{"id":"https://openalex.org/C509974204","wikidata":"https://www.wikidata.org/wiki/Q180507","display_name":"Radiation therapy","level":2,"score":0.2964000105857849},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.27309998869895935},{"id":"https://openalex.org/C2778822529","wikidata":"https://www.wikidata.org/wiki/Q1951525","display_name":"Progressive disease","level":3,"score":0.2599000036716461},{"id":"https://openalex.org/C2780456651","wikidata":"https://www.wikidata.org/wiki/Q238512","display_name":"Fluorouracil","level":3,"score":0.25690001249313354},{"id":"https://openalex.org/C2993158029","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colon adenocarcinoma","level":4,"score":0.25060001015663147}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.3389/fonc.2026.1933091","doi":"https://doi.org/10.3389/fonc.2026.1933091","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fonc.2026.1933091","pdf_url":"https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1933091/pdf","source":{"id":"https://openalex.org/S2596394214","display_name":"Frontiers in Oncology","issn_l":"2234-943X","issn":["2234-943X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Oncology","raw_type":"journal-article"},{"id":"pmh:oai:doaj.org/article:a666217d83e24cfea01a761338c0edc2","doi":null,"is_oa":false,"landing_page_url":"https://doaj.org/article/a666217d83e24cfea01a761338c0edc2","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Frontiers in Oncology, Vol 16 (2026)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.3389/fonc.2026.1933091","doi":"https://doi.org/10.3389/fonc.2026.1933091","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fonc.2026.1933091","pdf_url":"https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1933091/pdf","source":{"id":"https://openalex.org/S2596394214","display_name":"Frontiers in Oncology","issn_l":"2234-943X","issn":["2234-943X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Oncology","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9907000064849854,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Case Report","id":"https://openalex.org/study-designs/case-report"}],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7224457214.pdf","grobid_xml":"https://content.openalex.org/works/W7224457214.grobid-xml"},"referenced_works_count":17,"referenced_works":["https://openalex.org/W242040007","https://openalex.org/W2032454374","https://openalex.org/W2075121084","https://openalex.org/W2114005284","https://openalex.org/W2125447919","https://openalex.org/W2143743735","https://openalex.org/W2147834058","https://openalex.org/W2411596490","https://openalex.org/W2417825232","https://openalex.org/W2728001194","https://openalex.org/W2963672692","https://openalex.org/W3003103377","https://openalex.org/W4317862819","https://openalex.org/W4380887702","https://openalex.org/W4407236339","https://openalex.org/W4410765430","https://openalex.org/W7159695221"],"related_works":["https://openalex.org/W4410765430","https://openalex.org/W4388652838","https://openalex.org/W4385700891","https://openalex.org/W1970934973","https://openalex.org/W4416268114","https://openalex.org/W2066712926","https://openalex.org/W205536999","https://openalex.org/W7133243227","https://openalex.org/W7136963632","https://openalex.org/W2339834095"],"abstract_inverted_index":{"Urachal":[0],"adenocarcinoma":[1,33],"is":[2,14,125],"a":[3,78],"rare":[4],"malignancy":[5],"without":[6],"prospective":[7],"treatment":[8],"trials.":[9],"Management":[10],"of":[11,56,75,80,107,130],"metastatic":[12,31,115],"disease":[13,85],"typically":[15],"extrapolated":[16],"from":[17],"colorectal":[18],"cancer":[19],"(CRC)":[20],"due":[21,72],"to":[22,53,73,88],"histologic":[23],"and":[24,58,63],"molecular":[25],"similarities.":[26],"An":[27],"80-year-old":[28],"woman":[29],"with":[30,93],"urachal":[32,116],"received":[34],"sequential":[35],"CRC-based":[36,132],"therapy":[37],"including":[38,134],"first-line":[39],"CAPOX":[40],"plus":[41,45,49,95],"bevacizumab,":[42,46,50],"second-line":[43],"FOLFIRI":[44],"third-line":[47,112],"trifluridine/tipiracil":[48,94],"in":[51,60,110],"addition":[52],"brief":[54],"administration":[55],"regorafenib":[57],"fruquintinib":[59],"the":[61,102,111,128],"fourth-":[62],"fifth-line":[64],"setting.":[65],"Oxaliplatin":[66],"was":[67,120],"discontinued":[68],"after":[69],"one":[70],"cycle":[71],"worsening":[74],"vision":[76],"on":[77],"background":[79],"pre-existing":[81],"retinopathy.":[82],"The":[83],"longest":[84],"control":[86],"(time":[87],"progression":[89],"~11":[90],"months)":[91],"occurred":[92],"bevacizumab.":[96],"To":[97],"our":[98],"knowledge,":[99],"this":[100,108],"represents":[101],"first":[103],"report":[104],"describing":[105],"use":[106,129],"combination":[109],"setting":[113],"for":[114,127],"carcinoma.":[117],"Overall":[118],"survival":[119],"27":[121],"months.":[122],"This":[123],"case":[124],"hypothesis-generating":[126],"modern":[131],"therapies,":[133],"anti-VEGF\u2013containing":[135],"combinations.":[136]},"counts_by_year":[],"updated_date":"2026-11-01T11:40:01.658920","created_date":"2026-10-30T00:00:00"}